Iron metabolism and fungal infections in patients with haematological malignancies.

Survival of Aspergillus fumigatus in serum involves removal of iron from transferrin: the role of siderophores. Infect Immun (2004) 1.28

Iron acquisition from transferrin by Candida albicans depends on the reductive pathway. Infect Immun (2005) 1.22

Host iron withholding demands siderophore utilization for Candida glabrata to survive macrophage killing. PLoS Pathog (2011) 1.03

Lessons about the pathogenesis and management of aspergillosis from studies in chronic granulomatous disease. Trans Am Clin Climatol Assoc (2007) 0.93

Elevation of serum ferritin is associated with the outcome of patients with newly diagnosed multiple myeloma. Korean J Intern Med (2009) 0.88

Iron overload in patients undergoing hematopoietic stem cell transplantation. Adv Hematol (2010) 0.87

Conflicting interests in the pathogen-host tug of war: fungal micronutrient scavenging versus mammalian nutritional immunity. PLoS Pathog (2014) 0.86

Serum ferritin in acute leukaemia at presentation and during remission. Br Med J (1975) 1.57

Hydroxamate siderophore production by opportunistic and systemic fungal pathogens. Infect Immun (1983) 1.49

Ferritin synthesis in normal and leukaemic leukocytes. Nature (1974) 1.48

Ferritinaemia in leukaemia and Hodgkin's disease. Br J Cancer (1973) 1.37

REVERSAL OF SERUM FUNGISTASIS BY ADDITION OF IRON. J Invest Dermatol (1964) 1.26

Effects of iron and desferrioxamine on Rhizopus infection. Mycopathologia (1990) 1.25

Elevated serum iron, low unbound transferrin and candidiasis in acute leukemia. Blood (1969) 1.25

Ferritin in blood cells from normal subjects and patients with leukaemia. Br J Haematol (1974) 1.13

Siderophore production by the pathogenic yeast, Candida albicans. Biochem Biophys Res Commun (1985) 1.04

Quantitation of ferritin iron in plasma, an explanation for non-transferrin iron. Blood (1988) 0.95

Transferrin in disease II: defects in the regulation of transferrin saturation with iron contribute to susceptibility to infection. Am J Clin Pathol (1984) 0.92

Fungistatic mechanism of human transferrin for Rhizopus oryzae and Trichophyton mentagrophytes: alternative to simple iron deprivation. Infect Immun (1983) 0.90

Serum ferritin concentration in untreated Hodgkin's disease. Br J Cancer (1976) 0.87

Association of reduced total iron binding capacity and fungal infections in leukemic granulocytopenic patients. J Clin Oncol (1986) 0.82

Serum ferritin and Hodgkin's disease. Scand J Haematol (1985) 0.81

The measurement of ferritin in the leukemic blasts with a "sandwich" type enzyme immunoassay method. Cancer (1983) 0.80

[Serumferritin in patients with malignant lymphomas (author's transl)]. Klin Wochenschr (1977) 0.79

[Ferritin in acute leukemia. Serum ferritin concentration as a nonspecific tumor marker for M1 and M2 myeloid leukemia]. Med Klin (Munich) (1991) 0.79

Intestinal mucormycosis in a hemodialysis patient treated with desferrioxamine. Acta Pathol Jpn (1991) 0.79

Bleomycin-reactive iron in patients with acute non-lymphocytic leukemia. FEBS Lett (1992) 0.79

Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia (1999) 4.09

Community outbreaks of asthma associated with inhalation of soybean dust. Toxicoepidemiological Committee. N Engl J Med (1989) 3.16

Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia (2007) 1.99

A role for a rat homolog of staufen in the transport of RNA to neuronal dendrites. Neuron (2001) 1.94

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol (2005) 1.88

High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol (1999) 1.84

Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia (1999) 1.83

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia (2006) 1.73

Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia (2010) 1.66

Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol (1998) 1.55

Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia (1999) 1.55

Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia (2003) 1.52

Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: phenotypic and genomic differences. Am J Hematol (1993) 1.48

Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology. Haematologica (1998) 1.48

1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells. Leuk Res (1983) 1.48

SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. Leukemia (2012) 1.45

Minimal residual disease in leukaemia patients. Lancet Oncol (2001) 1.43

Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol (2001) 1.43

Citron binds to PSD-95 at glutamatergic synapses on inhibitory neurons in the hippocampus. J Neurosci (1999) 1.43

Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Bone Marrow Transplant (1999) 1.41

Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation. Bone Marrow Transplant (2004) 1.41

Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood (1989) 1.31

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia (2013) 1.30

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia (2009) 1.29

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant (2006) 1.29

Gerontogenes mediate health and longevity in nematodes through increasing resistance to environmental toxins and stressors. Exp Gerontol (2000) 1.28

Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia (2005) 1.27

Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia (2005) 1.26

BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL). Leukemia (2000) 1.24

Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol (2000) 1.23

Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. Leukemia (2001) 1.22

High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol (2003) 1.20

Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia (2006) 1.20

BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant (1997) 1.19

Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood (1998) 1.17

Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant (2003) 1.14

Molecular characterization of acute myeloblastic leukemia according to the new WHO classification: a different distribution in Central-West Spain. Haematologica (2001) 1.12

Immunophenotypic analysis of the TCR-Vbeta repertoire in 98 persistent expansions of CD3(+)/TCR-alphabeta(+) large granular lymphocytes: utility in assessing clonality and insights into the pathogenesis of the disease. Am J Pathol (2001) 1.11

Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia (2002) 1.11

Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant (2001) 1.10

The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol (2007) 1.10

Chronic T cell lymphocytosis: a review of 21 cases. Br J Haematol (1984) 1.10

High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol (2003) 1.08

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia (2012) 1.07

Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia (2005) 1.05

Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood MHC II+/lineage- cells. Clin Exp Immunol (1999) 1.05

Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial. Bone Marrow Transplant (2004) 1.04

Comparative analysis of the morphological, cytochemical, immunophenotypical, and functional characteristics of normal human peripheral blood lineage(-)/CD16(+)/HLA-DR(+)/CD14(-/lo) cells, CD14(+) monocytes, and CD16(-) dendritic cells. Clin Immunol (2001) 1.04

Cell surface markers in multiple myeloma. Mayo Clin Proc (1994) 1.04

Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study. Bone Marrow Transplant (2004) 1.04

Flow cytometric analysis of cytokine production by normal human peripheral blood dendritic cells and monocytes: comparative analysis of different stimuli, secretion-blocking agents and incubation periods. Cytometry (2001) 1.02

BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation. Leukemia (2001) 1.02

Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol (1996) 1.02

The membrane phenotype of hairy cell leukemia: a study with monoclonal antibodies. Semin Oncol (1984) 1.00

Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma (1998) 0.99

Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol (1996) 0.99

Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol (2001) 0.99

Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. Haematologica (2005) 0.98

Periphery to centre quality control of sputum smear microscopy and 'rapid fading' of Ziehl-Neelsen staining. Int J Tuberc Lung Dis (2000) 0.98

Characterization of blast cells in chronic granulocytic leukaemia in transformation, acute myelofibrosis and undifferentiated leukaemia. I. Ultrastructural morphology and cytochemistry. Br J Haematol (1985) 0.97

Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. Br J Haematol (1986) 0.97

Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia (2005) 0.96

Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol (1998) 0.96

Using the Spinal Cord Independence Measure III to measure functional recovery in a post-acute spinal cord injury program. Spinal Cord (2009) 0.96

Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol (2000) 0.94

Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther (1996) 0.94

Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem (1999) 0.94

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia (2002) 0.93

Bortezomib in multiple myeloma. Best Pract Res Clin Haematol (2007) 0.93

Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol (2003) 0.92

Evaluation of a CD61 MoAb method for enumeration of platelets in thrombocytopenic patients and its impact on the transfusion decision-making process. Transfusion (2001) 0.92

Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not active ethanol consumption. Hepatology (1997) 0.92

Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia (2003) 0.91

Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol (2001) 0.91

Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol (1992) 0.91

Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol (1996) 0.91

Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer (2004) 0.90

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia (2013) 0.90

Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia (2001) 0.90

Immunophenotypic characterisation of acute leukaemia after polycythemia vera. J Clin Pathol (1993) 0.90

Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant (2001) 0.89

De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia (2000) 0.89

Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia (2004) 0.89

Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. Leukemia (2007) 0.89

Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant (2008) 0.89

6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol (2007) 0.88

Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment. Cell Transplant (2012) 0.87

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia (2004) 0.87

Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol (2004) 0.87

Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Pathol Biol (Paris) (1999) 0.87

Cimetidine and eosinophilic fasciitis. Ann Intern Med (1983) 0.86

Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration. Am J Pathol (1996) 0.86